Streetwise Medical Devices Articles

Medical Device Firm to Launch Trials for Treatment Targeting $12 Billion Incontinence Market
Source: Streetwise Reports  (2/14/18)
Anthony Vendetti, an analyst with Maxim Group, shared the results both of a pilot study for stress urinary incontinence and of a recent equity raise by this company.
More >

Medical Device Firm Boosts Quarterly Revenue 50% YOY
Source: Streetwise Reports  (1/31/18)
A Maxim Group report noted the recently announced revenue achieved and anticipated by this producer of cancer treatment devices. More >

Firm Focused on Women's Health Posts 'Record' Sales of Treatment Device
Source: Streetwise Reports  (1/10/18)
A company marketing a product designed to enhance women's sexual function announced preliminary financial results for Q4/17 that caught the attention of several analysts. More >

Immunotherapy Firm Gets Green Light for Pivotal Trial From FDA
Source: Streetwise Reports  (12/27/17)
Jason Kolbert, an analyst with Maxim Group, described the study, which enables this biotech's device to be used in patients undergoing heart surgery and will measure its effectiveness in reducing a common post-surgical side effect.
More >

Analysts Say Medical Device Firm Sees Record Quarterly Revenue Growth, 120% YOY
Source: Streetwise Reports  (11/29/17)
Following the company's release of its latest financial report, three analysts weighed in on the results. More >

Biotech Receives Device Approval in Five More Countries; Revenue Up 122% YOY
Source: Streetwise Reports  (10/25/17)
Maxim Group reported on this firm's Q3/17 earnings, as well as its progress in obtaining international regulatory clearances for its medical system.
More >

Telemedicine Platform Is Quickly Gaining Traction in Fast Growing Market
Source: Streetwise Reports  (10/5/17)
The rapid increase in the incidence of chronic diseases and the need to reduce healthcare costs have led to the growth in telemedicine, which has companies racing to bring new products to market. More >

Maxim Raises Target Price of Biotech Company
Source: Streetwise Reports  (8/16/17)
A year-over-year increase in sales of its flagship product, and the prospect that its technology could be used to promote the efficacy of cell therapies, helped spur a target price increase on this biotech.
More >

Loan Provides Driver for Growth for Medical Device Firm
Source: Streetwise Reports  (8/2/17)
Brian Marckx, analyst with Zacks Small-Cap Research, reports that a $20 million loan received by a U.S.-based medical device company could further fuel growth. More >

Innovative Company Focused on Women's Health Completes Record-Breaking Quarter
Source: The Life Sciences Report  (5/24/17)
Viveve Medical's Q1/17 results beat expectations, an accomplishment that was welcomed by several industry analysts. More >

Viveve Medical Posts Record Revenues and Analysts Foresee Continued Growth
Source: The Life Sciences Report  (2/22/17)
As Viveve Medical ramped up its U.S. sales force, reported record earnings, increased the number of countries that have given regulatory approval and saw the results of its VIVEVE I clinical study published in the Journal of Sexual Medicine, a trio of analysts took notice. More >

Bob Moriarty

Luminor Drives the Scout DS Forward
Source: Bob Moriarty for The Life Sciences Report  (2/6/17)
Veteran investor Bob Moriarty discusses Luminor Medical Technologies, whose Scout DS technology offers a noninvasive diabetic screen, measuring blood-sugar levels without taking blood. More >

Colin Lee Novick

Companies Flocking to Japan for Biotech Deals
Source: Colin Lee Novick for The Life Sciences Report  (2/1/17)
For the last two years, Japan has been at the forefront of accelerated approval for regenerative medicine products and has seen lots of licensing and contract manufacturing deals and M&A activity. Tokyo-based Colin Lee Novick, managing director of CJ PARTNERS, surveys the landscape, discussing recent tie-ups, the effects of the recently passed 21st Century Cures Act in the U.S., and what may lie ahead. More >

Viveve's Technology for Women's Sexual Dysfunction Receives Regulatory Approval in 49 Countries
Source: The Life Sciences Report  (12/21/16)
The last several months have been active ones for Viveve: The results of the VIVEVE I clinical trial were accepted for publication in the Journal of Sexual Medicine, third-quarter financial results beat expectations, and the Viveve system has received regulatory approvals in Brazil, U.A.E. and Lebanon and FDA 510(k) clearance in the U.S. More >

Anthony Vendetti

Viveve's Treatment for Improving Women's Sexual Function May Leapfrog the Competition
Source: The Life Sciences Report  (10/5/16)
Private-pay aesthetic procedures constitute a trend in medical devices, according to Anthony Vendetti, Director of Research at Maxim Group. These nonreimbursable types of procedures have seen rapid growth in the past decade. In this interview with The Life Sciences Report, Vendetti discusses Viveve Medical, which is attempting to leapfrog the competition to get FDA approval to use its patented radiofrequency technology to improve women's sexual function. More >

Bob Moriarty

Imagin, a Better Way to Detect Bladder Cancer
Source: Bob Moriarty for The Life Sciences Report  (9/20/16)
Bob Moriarty profiles Imagin Medical, a company that has developed a new way of detecting bladder cancer through endoscopes. More >

Stuart Roberts

The ASX: Investing in an Emerging Biotech Frontier
Source: Stuart Roberts for The Life Sciences Report  (8/10/16)
Concerned about investing in the life sciences in the United States, where markets have slumped in 2016 and the presidential election furthers volatility? NDF Research Founder Stuart Roberts makes an argument for taking a look at investment opportunities Down Under. More >

How Sick Will Brexit Make Biotech and Pharma?
Source: Tracy Salcedo of The Life Sciences Report  (6/29/16)
In tandem with the broader markets, the biotech indices reeled on the news of Britain's vote to exit the European Union. Given the uncertainty and dire economic forecasts, The Life Sciences Report has reviewed commentary from sector experts and biotech publications to help investors understand what Brexit might mean for the industry. More >

Advantage: Australia. Biotechs Surge Ahead in Regenerative Medicine and Immuno-Oncology
Source: George S. Mack of The Life Sciences Report  (5/11/16)
Biotech and medtech startups are not confined to the U.S. and Europe. Unmet medical needs exist all over the globe, and they create a powerful vacuum that sucks in bright minds and risk-taking capitalists. Australia is a good example: The regulatory environment supports first-in-human experimentation and entrepreneurship. Healthcare Analyst Dennis Hulme of Edison Investment Research is headquartered in Sydney, and in this interview with The Life Sciences Report, he cites a group of Australian medtech and biotech names that investors should look at very carefully. More >

Lisa Crossley

Moseda Joins Telus and Apple in the $20B Patient Home Monitoring Sector
Source: Special to The Life Sciences Report  (3/29/16)
Because chronic conditions are difficult to manage by patients at home, with complications, hospitalizations and other expensive interventions sometimes necessary, they account for more than 75% of healthcare costs worldwide. To meet this need, Moseda Technologies has developed innovative, secure mobile software solutions for the $20 billion community/home care market. In this interview with The Life Sciences Report, Moseda's CEO, Dr. Lisa Crossley, describes the company's comprehensive hardware and software solution, dubbed CareKit, which allows patients to receive high-quality care in the home, improving health outcomes and enhancing quality of life for patients and families while reducing the cost of care. More >

Marcel Wijma

Circling the Globe for Uncommon Biotech Opportunities: Van Leeuwenhoeck's Marcel Wijma
Source: George S. Mack of The Life Sciences Report  (2/17/16)
Stock analysts fall into a few different categories. There are buyside analysts and sellside analysts, and then there are independent analysts commissioned by companies to highlight underexposed business models and growth prospects. The independent analyst, such as Van Leeuwenhoeck's Marcel Wijma, normally works in the small- and micro-cap stock universe, where the buyside and sellside rarely go. In this interview with The Life Sciences Report, Wijma brings to light five diverse, overlooked small-cap biotech stocks from Canada, Europe and Australia that could bring huge returns to investor portfolios. More >

Stewart Washer

Advanced Stem Cell Manufacture Saves Lives and Prints Money: Stewart Washer of Cynata Therapeutics
Source: Peter Byrne of The Life Sciences Report  (2/3/16)
Cynata Therapeutics of Australia has carved a technological niche in the fast-advancing cell therapy market with a platform that renders the production of stem cell-based treatments for cancer and diseases of the immune system easy and affordable, saving lives and money. In this interview, Cynata's executive chairman Stewart Washer tells The Life Sciences Report why his company's technology, in studies for graft-versus-host disease, has proven itself a profit driver. More >

Bruce Campbell

Look North for Value-Priced Growth in Healthcare: StoneCastle's Bruce Campbell
Source: George S. Mack of The Life Sciences Report  (2/3/16)
Canada is a wellspring for natural resources and the industries built around them. But the country also encompasses healthcare-related businesses that are growing, generating cash flow and flourishing. Bruce Campbell of StoneCastle Investment Management has managed both U.S. and Canadian portfolios, and he knows both spheres. As a hedge fund and mutual fund manager concentrating on Canadian companies, he has made a specialty in acquisitions of cash-generating healthcare companies. In this interview with The Life Sciences Report, Campbell discusses seven small-cap growth names, all of which have reached share-price levels that do not reflect their capacity to grow. Some may offer rare opportunities to buy at risk-mitigated value prices. More >

The 2016 Small-Cap Biotech Watchlist Debuts at the Biotech Showcase
Source: Tracy Salcedo of The Life Sciences Report  (1/27/16)
This may prove a challenging year for small-cap biotechs, but the five analysts who selected companies for inclusion on The Life Sciences Report's 2016 Small-Cap Biotech Watchlist believe these companies have a good shot at producing innovative products in a variety of indications and producing value for investors. Discovery, it turns out, is not just about finding the cure for a particular disease; it's also about finding the companies best poised to reach that goal. More >

Rick Mills

Rick Mills: How to Profit from the Demands of a Growing World Population
Source: JT Long of The Gold Report  (1/21/16)
As the world prepares to house, feed and care for 9.7 billion people, Ahead of the Herd founder Rick Mills is looking for the companies that will profit from the silent tsunami of demand creeping up on resource and healthcare providers. In this interview with The Gold Report, Mills reveals the six companies he thinks are well positioned in their respective sectors to ride this population wave to profits. More >

Showing Results: 1 to 25 of 168 Next

Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts

"For Q4/17, DRRX recorded revenue of $19.5M compared to $3.5M in Q4/16."
– Grant Zeng, Zacks Investment Research, Zacks Small-Cap Research
"VIVE's cash as of Q4/17 was $20.7M."
– Jeff Cohen, Ladenburg Thalmann